The new crown vaccine's new strengthening needle is urgently used, how is the protective effect on Omikon

15.09.2022

Number of this text: 1449, the reading time is about 2 minutes old

Introduction: With the extensive vaccination of my country's new crown vaccine, basic immunization has been accelerated. Many vaccine companies have slowed down the slow sales of new crown vaccines. What are the newly approved enhanced needles?

Author | First Finance Lin Zhiyin

Earlier this month, the State Drug Administration has agreed to incorporate two new new crown vaccines as an emergency use, one of which is the reorganized new coronary virus fusion protein vaccine of Lizhu Group ("Likang V-01").

First Financial reporter learned from Lizhu Group (000513.SZ, 01513.HK) that the company has done the preparation of Likang V-01 vaccination. Some cities have already put forward procurement demand to the provincial disease control center.

As of now, with the Likang V-01, 9 new crown vaccines have been approved for marketing or emergency use. Most of these vaccines can also be used on the basis of two-needle activity vaccine for homologous or heterogeneous. Strengthen use. However, with the widespread vaccination of my country's new crown vaccine, basic immunization has been accelerated, and many vaccine companies have slowed down the slow sales of new crown vaccines. Where is the market competition opportunity of Likang V-01? How to achieve differentiated competition?

Zhu Baoguo, chairman of Health Yuanlizhu Group, told the First Financial reporter that the new crown vaccine is still one of the most effective measures to fight against the new crown virus. Inocular need to reinforce the need to reduce the inpatient and death risk caused by the mutation of Omikon, but also the risk of death. It can further reduce the breakthrough infection caused by Omikon. Faced with the continuously mutant Omikon virus, the market still has a large market demand for high -protection new crown vaccines. From the perspective of the domestic market, the third in vaccination and child vaccination rate of the elderly still need to be improved. From the perspective of foreign markets, the distribution of vaccines is still very uneven, and the overall vaccination rate also has a lot of room for improvement.

Zhu Baoguo said that compared with homologous enhancement, heterogeneous enhancement can provide stronger protection. In the subsequent strengthening of the needle market and the market with basic diseases and high-risk groups (such as the elderly), it will be the direction of Likang V-01.

Currently supporting Likang V-01 obtained the third phase of clinical trials of domestic emergency use. The design plan is to enhance the order on the basis of the two-needle activation vaccine (that is, heterogeneous vaccination). This is also the world's first development. The three -phase clinical trials that are enhanced on the basis of living seedlings.

Hu Zhenxiang, deputy general manager of Lizhu Ming Group, a subsidiary of Lizhu Group, told the First Financial Reporter that the sequence of Likang V-01 strengthened the results of the third phase of clinical trials that the absolute protection of the vaccine was 61.35%, and more than 90%of the finals cases were more than 90%or more. In order to Omikon, it shows that it has a good attack on Omikon, and this protection is equivalent to that of the MRNA vaccine itself or heterogeneous strengthening.

"Data from the real world and Brazil real world research data show that the absolute protection rate is 62.5%on the basis of the two -shot MRNA vaccine, which is 62.5%; It is 56.8%. However, on the basis of the two-shot extinguishing seedlings, the Likang V-01 sequence is strengthened, and the absolute protection rate is 61.35%. 61.19%, of which the protection of people with basic diseases is as high as 71.83%. In terms of safety, the safety of Likang V-01 is significantly better than the MRNA vaccine and adenovirus vaccine. AE) is mild, of which the collection of syllable AE (pain, headache, fatigue, fever, non-vaccinating muscle pain) data is significantly lower than the MRNA vaccine. " Fast effects, high antibody titration, and good durability, such as 7 days of vaccination, will take effect for 7 days, and can achieve excellent protection effects 14 days after vaccination. It can also be used as emergency vaccination.

It is worth mentioning that when Likang V01 was launched in the third phase of clinical trials, the world's popular Omikon mutant strains were mainly BA.1. Today, BA.4 and BA.5 are replacing other Omiko Rongya Aya Types, how are the vaccines in the world, what is the effect of the vaccine for BA.4 and BA.5?

The Lizhu Group said that from the perspective of company research, Likang V-01 still has good neutralization for BA.4 and BA.5.

In addition to the domestic market, Likang V-01 is also planning to seek overseas listing. Lizhu Group said that Likang V-01 EUA (Emergency Use Authorization) information in the Philippines, Indonesia and Malaysia has been submitted and the WHO certification is performed simultaneously.

- END -